Spruce Biosciences Inc (SPRB)

$90.44 +0.28 (0.31%)
Market Cap 95.48M
Revenue (ttm) 4.91M
Net Income (ttm) -53.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,080.24%
Debt to Equity Ratio 0.10
Volume 47,600
Avg Vol 706,878
Day's Range N/A - N/A
Shares Out 1.07M
Stochastic %K 43%
Beta 3.45
Analysts Sell
Price Target $209.50

Company Profile

Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders. The company develops TA-ERT, a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase, which is an enzyme replacement therapy for patients with Sanfilippo Syndrome Type B. It also develops Tildacerfont for treating a highly debilitating mental disorder characterized by depressed mood with cognitive-affective and somatic changes, includ...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 655 4168
Address:
611 Gateway Boulevard, Suite 740, South San Francisco, United States
MegaFat
MegaFat Dec. 5 at 1:30 AM
$QCLS bro you watched $SPRB? THIS GUY IS A PROBLEM FOR THE SHORTS AND THEY SHOULD KNOW IT. MARTIN SKIRELLI SHOULD DRIVE FEAR IN THESE SHORTS IF THEY HAVE HALF A BRAIN
0 · Reply
Bouge123
Bouge123 Dec. 5 at 1:00 AM
$QCLS $SPRB $QCLS but theres no 13G filling... how many shares were purchased by Martin Skirelli...
0 · Reply
MegaFat
MegaFat Dec. 5 at 12:49 AM
$QCLS same guy behind $SPRB MARTIN SKIRELLI Q/C Technologies Inc. (QCLS) shares soared over 60% on Thursday, extending Wednesday’s gains as American pharma investor Martin Shkreli announced that he had purchased the company’s shares. “We bought a photonic/optical computing stock: $QCLS. I'm convinced that the answer to frontier computing is optical, not quantum. we're calling it "quantum class" so investors understand it,” Shkreli said in a post on X. He also added that he would join the company as CEO if President Trump allowed it.
0 · Reply
MegaFat
MegaFat Dec. 4 at 10:55 PM
$QCLS well after $SPRB THE SHOULD KNOW THE ONLY WHITE MEMBERVOF THE WUTANG CLAN DOESN'T PLAY
0 · Reply
MegaFat
MegaFat Dec. 4 at 10:30 PM
$QCLS fun fact MARTIN SKIRRELI WASBE BEHIND $SPRB PUSH
0 · Reply
ErikTon
ErikTon Dec. 4 at 7:11 PM
$SPRB there is no ifs, ands, or buts this is going to $69
1 · Reply
jlucer53
jlucer53 Dec. 4 at 4:18 PM
$SPRB anyone have any qualified reasons Fda would not approve on phase 2? Data seems solid and no one is arguing it. They agreed in a meeting that the biomarker is what they need to chase so they are aligned. The patients have been on the med for 3-5 years. I don't see why they wouldnt approve. Anyone?
0 · Reply
AverageTraders
AverageTraders Dec. 4 at 2:11 AM
Banked up $8.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He calls them early before anyone else. Love adding before the runs✅ Watching $NVDA $WOLF $NUAI $SPRB !
0 · Reply
ODucks
ODucks Dec. 3 at 8:30 PM
$CAPR Looks like this ride might extend through the week like $SPRB and so many others before it.
0 · Reply
BanditKnight47
BanditKnight47 Dec. 3 at 2:40 PM
$CAPR $SPRB VIBES!
1 · Reply
Latest News on SPRB
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Nov 10, 2025, 4:05 PM EST - 24 days ago

Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

Oct 7, 2025, 10:38 AM EDT - 2 months ago

Spruce: BTD For TA-ERT For MPS IIIB Could Ignite BLA Submission With Added Bonuses (Rating Upgrade)

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Oct 7, 2025, 9:44 AM EDT - 2 months ago

This Biotech Stock Soared 1,400%. Investors Are Optimistic About Its Rare-Disease Drug.

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Oct 6, 2025, 8:00 AM EDT - 2 months ago

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Sep 15, 2025, 7:00 AM EDT - 2 months ago

Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

MegaFat
MegaFat Dec. 5 at 1:30 AM
$QCLS bro you watched $SPRB? THIS GUY IS A PROBLEM FOR THE SHORTS AND THEY SHOULD KNOW IT. MARTIN SKIRELLI SHOULD DRIVE FEAR IN THESE SHORTS IF THEY HAVE HALF A BRAIN
0 · Reply
Bouge123
Bouge123 Dec. 5 at 1:00 AM
$QCLS $SPRB $QCLS but theres no 13G filling... how many shares were purchased by Martin Skirelli...
0 · Reply
MegaFat
MegaFat Dec. 5 at 12:49 AM
$QCLS same guy behind $SPRB MARTIN SKIRELLI Q/C Technologies Inc. (QCLS) shares soared over 60% on Thursday, extending Wednesday’s gains as American pharma investor Martin Shkreli announced that he had purchased the company’s shares. “We bought a photonic/optical computing stock: $QCLS. I'm convinced that the answer to frontier computing is optical, not quantum. we're calling it "quantum class" so investors understand it,” Shkreli said in a post on X. He also added that he would join the company as CEO if President Trump allowed it.
0 · Reply
MegaFat
MegaFat Dec. 4 at 10:55 PM
$QCLS well after $SPRB THE SHOULD KNOW THE ONLY WHITE MEMBERVOF THE WUTANG CLAN DOESN'T PLAY
0 · Reply
MegaFat
MegaFat Dec. 4 at 10:30 PM
$QCLS fun fact MARTIN SKIRRELI WASBE BEHIND $SPRB PUSH
0 · Reply
ErikTon
ErikTon Dec. 4 at 7:11 PM
$SPRB there is no ifs, ands, or buts this is going to $69
1 · Reply
jlucer53
jlucer53 Dec. 4 at 4:18 PM
$SPRB anyone have any qualified reasons Fda would not approve on phase 2? Data seems solid and no one is arguing it. They agreed in a meeting that the biomarker is what they need to chase so they are aligned. The patients have been on the med for 3-5 years. I don't see why they wouldnt approve. Anyone?
0 · Reply
AverageTraders
AverageTraders Dec. 4 at 2:11 AM
Banked up $8.4K profits on that run! Thank you! Made my whole month! Make sure you FOLLOW @ICEMAN_ALERTS below, Great trader!! He calls them early before anyone else. Love adding before the runs✅ Watching $NVDA $WOLF $NUAI $SPRB !
0 · Reply
ODucks
ODucks Dec. 3 at 8:30 PM
$CAPR Looks like this ride might extend through the week like $SPRB and so many others before it.
0 · Reply
BanditKnight47
BanditKnight47 Dec. 3 at 2:40 PM
$CAPR $SPRB VIBES!
1 · Reply
ReadyMate
ReadyMate Dec. 3 at 2:05 PM
$CAPR wondering what could happen today ? Look at $SPRB … went from 8 to 200 in October (on news that was remotely as good as our Capricor news ) … so don’t sell when she opens at 20!!!!
0 · Reply
JarvisFlow
JarvisFlow Dec. 3 at 1:44 PM
Leerink Partners updates rating for Spruce Biosciences ( $SPRB ) to Outperform, target set at 160.
0 · Reply
theflynews
theflynews Dec. 2 at 6:22 PM
Biotech Alert: Searches spiking for these stocks today - $SPRB - https://thefly.com/permalinks/entry.php/SPRBid4248758?1764699751C38
0 · Reply
HalfTrader
HalfTrader Dec. 2 at 2:29 PM
$SPRB long term hold.
0 · Reply
Stmkr
Stmkr Dec. 1 at 10:07 PM
$SPRB PRV renewed. Good news for SPRB (I dont think they would be fast enough to get approval by Sep.2026). Now they have time
0 · Reply
neelsen01
neelsen01 Dec. 1 at 9:52 PM
$SPRB this is the small window of opportunity. I’m not sure how low the stock will be or for how long …
1 · Reply
neelsen01
neelsen01 Dec. 1 at 9:51 PM
$SPRB S3 went in effect November 26…
0 · Reply
perfectson
perfectson Dec. 1 at 8:58 PM
$SPRB this is likely end of year selling for tax purposes. This is a Q1 play for the BLA - so all types of EOY shenanigans can/will happen before then.
0 · Reply
_www_larval_com_
_www_larval_com_ Dec. 1 at 8:51 PM
$CNCK -4%[151%] $SLMT 4%[-8%] $AMBR 3%[-12%] $CAPR -3%[22%] $SPRB -3%[-18%] most notable movement into the final minutes of trading.
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Dec. 1 at 8:29 PM
Comparing trending tickers $WOLF vs $SPRB: WOLF is up 8.48% to $22.00 with a volume of 3.3M shares, slightly below its average of 4.7M. Meanwhile, SPRB has dropped 15.02% to $84.98 on a volume of 459.4K, which is more than 3 times its usual volume of 141.3K. While WOLF shows solid gains on a slightly quieter day, SPRB's significant price drop comes amidst much higher than normal trading activity.
0 · Reply
vcpchris1
vcpchris1 Dec. 1 at 8:23 PM
$SPRB $GTLB $MSTR $QQQ
0 · Reply
itsphd
itsphd Dec. 1 at 7:46 PM
$SPRB When this comes down to 60 I can buy some more, nothing has changed in my view but this is a very small portion of my investments.
0 · Reply